

PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE				
XRAY-CHEST				
IMPRESSION	NO ABNORMALITY DETECT	ED		
ECG				
ECG	NORMAL SINUS RHYTHM			
MEDICAL HISTORY				
RELEVANT PRESENT HISTORY	NOT SIGNIFICANT			
RELEVANT PAST HISTORY	P/H/O 1 C- SECTION IN 20	19		
RELEVANT PERSONAL HISTORY MENSTRUAL HISTORY (FOR FEMALES)	BILATERAL LASIK 20 YEAR NOT SIGNIFICANT REGUALR	S BACK		
LMP (FOR FEMALES)	20/11/2023			
OBSTETRIC HISTORY (FOR FEMALES)	G1,P1,A0,L1			
LCB (FOR FEMALES)	2019			
RELEVANT FAMILY HISTORY	NOT SIGNIFICANT			
OCCUPATIONAL HISTORY	NOT SIGNIFICANT			
HISTORY OF MEDICATIONS	NOT SIGNIFICANT			
ANTHROPOMETRIC DATA & BMI				
HEIGHT IN METERS	1.56	mts		
WEIGHT IN KGS.	48.0	Kgs		
BMI	20	BMI & Weight Status as followg/sqmts Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese		
GENERAL EXAMINATION				
MENTAL / EMOTIONAL STATE	NORMAL			
PHYSICAL ATTITUDE	NORMAL			
GENERAL APPEARANCE / NUTRITIONAL STATUS	HEALTHY			
BUILT / SKELETAL FRAMEWORK	AVERAGE			
FACIAL APPEARANCE	NORMAL			

NORMAL

NORMAL

UPPER LIMB

SKIN

P. V. Kipudia

Dr.Priyank Kapadia Physician









PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF			
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female		
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KHUSF130290321	DRAWN :		
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27		
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15		
8800465156				
Test Report Status <u>Preliminary</u>	Results Biologic	al Reference Interval Units		
LOWER LIMB	NORMAL			
NECK	NORMAL			
NECK LYMPHATICS / SALIVARY GLANDS	NOT ENLARGED OR TENDER			
THYROID GLAND	NOT ENLARGED			
TEMPERATURE	NORMAL			
PULSE	68/MIN			
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
BP	124/82 MM HG	mm/Hg		
	(SITTING)			
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	S1, S2 HEARD NORMALLY			
IURMURS	ABSENT			
RESPIRATORY SYSTEM				
SIZE AND SHAPE OF CHEST	NORMAL			
NOVEMENTS OF CHEST	SYMMETRICAL			
BREATH SOUNDS INTENSITY	NORMAL			
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)			
ADDED SOUNDS	ABSENT			
PER ABDOMEN				
APPEARANCE	NORMAL			
IVER	NOT PALPABLE			
SPLEEN	NOT PALPABLE			
CENTRAL NERVOUS SYSTEM				
HIGHER FUNCTIONS	NORMAL			
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
10TOR SYSTEM	NORMAL			
REFLEXES	NORMAL			
MUSCULOSKELETAL SYSTEM				
SPINE	NORMAL			

P. V. Equilia

Dr.Priyank Kapadia Physician

Page 2 Of 21

View Report







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biologica	al Reference Interval Units
JOINTS BASIC EYE EXAMINATION	NORMAL	
DISTANT VISION RIGHT EYE WITHOUT GLASSES DISTANT VISION LEFT EYE WITHOUT	6/12	
GLASSES NEAR VISION RIGHT EYE WITHOUT GLASSES NEAR VISION LEFT EYE WITHOUT GLASSES COLOUR VISION SUMMARY	N/6 N/6 NORMAL	
RELEVANT HISTORY RELEVANT GP EXAMINATION FINDINGS RELEVANT LAB INVESTIGATIONS	NOT SIGNIFICANT NOT SIGNIFICANT HEMOGLOBIN:- LOW, MCV:- LOW, MC	CH:- LOW
RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS	ESR:- HIGH URINE:- BLOOD DETECTED (+ + +), H HIGH NO ABNORMALITIES DETECTED 1) HEMOGLOBIN:- LOW, MCV:- LOW,	
	ADV:- TAKE MORE DIETARY IRON	
	2) ESR:- HIGH	
	ADV:- PHYSICIAN OPINION	
	3) URINE:- BLOOD DETECTED (+ + + - HIGH), RBC - HIGH, EPITHELIAL CELLS
	ADV:- DRINK PLENTY OF WATER, REP DAYS, USG ABDOMEN AND PHYSICIA	

Comments

OUR PANEL DOCTORS FOR NON-PATHOLOGY TESTS:-

CHECK UP DONE BY:- DR. NAMRATA AGRAWAL (M.B.B.S)

REPORT REVIEWED BY:- DR. PRIYANK KAPADIYA (M.B.B.S DNB MEDICINE)

RADIOLOGIST:- DR. SAHIL N SHAH (M.D.RADIOLOGY)

P. V. Kipudia

Dr.Priyank Kapadia Physician



Page 3 Of 21

View Report







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KHUSF130290321	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		
Test Report Status <u>Preliminary</u>	Results Biologic	al Reference Interval Units

P. V. Equilia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel: 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 4 Of 21







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF			
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KHUSF130290321 CLIENT PATIENT ID:	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15		
Test Report Status <u>Preliminary</u>	Results	Units		

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN**

NO ABNORMALITIES DETECTED TMT OR ECHO **CLINICAL PROFILE**

2D ECHO:-

NORMAL CHAMBERS AND VALVES.

GOOD LV SYSTOLIC FUNCTION. LVEF 60%. NO RWMA AT REST.

NO MR, AR, TR.

NORMAL LV COMPLIANCE.

5) NO PAH.

NO LV CLOT, VEGETATION OR PERICARDIAL EFFUSION.

IAS/IVS INTACT.

Interpretation(s) MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

P. V. Equilia

Dr.Priyank Kapadia Physician

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 5 Of 21





Test Report Status

Preliminary



Biological Reference Interval Units

PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KHUSF130290321	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		
(

Results

н	IAEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BI	ELOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	10.3 Low	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	4.22	3.8 - 4.8	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	4.56	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : COULTER PRINCIPLE	388	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED	32.2 Low	36.0 - 46.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	76.2 Low	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED	24.4 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED	32.0	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	17.6 High	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMETER	18.1		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	7.2	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : OPTICAL IMPEDENCE & MICROCSOPY	52	40 - 80	%
LYMPHOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	32	20 - 40	%
MONOCYTES METHOD : OPTICAL IMPEDENCE & MICROCSOPY	10	2.0 - 10.0	%

5

EOSINOPHILS

Dr.Miral Gajera Consultant Pathologist

Page 6 Of 21



%

View Details

1.0 - 6.0





PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 032 PATIENT ID : KHL CLIENT PATIENT ID: ABHA NO :	ISF130290321 DRAWN RECEIVED	:33 Years Female : 0 :25/11/2023 09:38:27 0 :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results	Biological Reference	ce Interval Units
METHOD : OPTICAL IMPEDENCE & MICROCSOPY BASOPHILS	1	0 - 1	%
METHOD : IMPEDANCE			
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED	2.37	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	1.46	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD : CALCULATED PARAMETER	0.46	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD : CALCULATED	0.23	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT METHOD : CALCULATED	0.05	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED PARAMETER	1.6		
MORPHOLOGY			
RBC METHOD : MICROSCOPIC EXAMINATION	MILD MICROCYTIC	HYPOCHROMIC, ANISOCYTOSI	S PRESENT(+).
WBC METHOD : MICROSCOPIC EXAMINATION	NORMAL MORPHOL	DGY	
PLATELETS METHOD : MICROSCOPIC EXAMINATION	ADEQUATE		
	NO PREMATURE CELLS ARE SEEN. MALARIAL PARASITE NOT DETECTED.		

METHOD : MICROSCOPIC EXAMINATION

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR =

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr.Miral Gajera Consultant Pathologist

Page 7 Of 21



View Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KHUSF130290321	DRAWN :	
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27	
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15	
8800465156			
		1	

Test Report Status	Preliminary	Results	Biological Reference Interval	Units
--------------------	--------------------	---------	--------------------------------------	-------

	HAEMATOLOGY		
MEDI WHEEL FULL BODY HEALTH CHECKUP	BELOW 40FEMALE		
ERYTHROCYTE SEDIMENTATION RATE (ESR BLOOD	R),EDTA		
E.S.R	28 High	0 - 20	mm at 1 hr
METHOD : WESTERGREN METHOD			
GLYCOSYLATED HEMOGLOBIN(HBA1C), ED BLOOD	TA WHOLE		
HBA1C	5.4	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
	100.0		
ESTIMATED AVERAGE GLUCOSE(EAG)	108.3	< 116.0	mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-**TEST DESCRIPTION** :-Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. **Decreased** in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

Diagnosing diabetes.
 Identifying patients at increased risk for diabetes (prediabetes).

Dr.Miral Gajera Consultant Pathologist

Page 8 Of 21



View Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

The ADA recommends	measurement of HbA1c (typically	3-4 times per year for type	1 and poorly controlled	type 2 diabetic patients, a	and 2 times per year for

well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
eAG gives an evaluation of blood glucose levels for the last couple of months.
eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicate diabetes control over 15 days.
2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HDF > 25% on alternate pattform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in

Page 9 Of 21

View Report



Vi<u>ew Details</u>





PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KHUSF130290321	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		
	I	

Test Report Status	Preliminary
--------------------	--------------------

Results

Biological Reference Interval Units

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP TYPE O METHOD : TUBE AGGLUTINATION RH TYPE POSITIVE METHOD : TUBE AGGLUTINATION

Interpretation(s) ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr.Miral Gajera Consultant Pathologist







PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : S	SELF
	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
	PATIENT ID : KHUSF130290321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		

		Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval	Units
--	--	--------------------	--------------------	---------	--------------------------------------	-------

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECKUP E	BELOW 40FEMALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD : HEXOKINASE	86	74 - 99	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : HEXOKINASE	85	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDL			
CHOLESTEROL, TOTAL	151	Desirable: < 200 BorderlineHigh: 200 - 239 High: > or = 240	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC			
TRIGLYCERIDES	40	Desirable: < 150 BorderlineHigh: 150 - 199 High: 200 - 499 Very High: > or = 500	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC			
HDL CHOLESTEROL	48	< 40 Low > or = 60 High	mg/dL
CHOLESTEROL LDL	95	Adult levels: Optimal < 100 Near optimal/above optimal 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL I:
NON HDL CHOLESTEROL	103	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	8.0	< or = 30	mg/dL
CHOL/HDL RATIO	3.2 Low	3.3 - 4.4	
LDL/HDL RATIO	2.0	0.5 - 3.0 Desirable/Low Risl 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	

ALE

Dr.Miral Gajera Consultant Pathologist

Page 11 Of 21







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321	AGE/SEX : 33 Years Female
F-703, LADO SARAL MEHRAULISOUTH WEST	CLIENT PATIENT ID: ABHA NO :	RECEIVED : 25/11/2023 09:38:27 REPORTED : 27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India			
Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk g	roup or recurrent ACS (within 1 year) despite LDL-C < or =	
	50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2 r	najor risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemia	A	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ		
	damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary		
	Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age > or = 45 years in males and > or = 55 years in females 3. Current Cigarette smoking or tobacco use			
2. Family history of premature ASCVD 4. High blood pressure			
5. Low HDL			

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug T	herapy
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL	0.39	Upto 1.2	mg/dL
BILIRUBIN, DIRECT	0.17	Upto 0.2	mg/dL
METHOD : DIAZO COLORIMETRIC BILIRUBIN, INDIRECT	0.22	0.00 - 1.00	mg/dL
TOTAL PROTEIN	7.4	6.4 - 8.3	g/dL
METHOD : COLORIMETRIC			
ALBUMIN	4.9	3.5 - 5.2	g/dL
METHOD : BROMOCRESOL GREEN			

Dr.Miral Gajera Consultant Pathologist

Page 12 Of 21







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KHUSF130290321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		

Test Report Status <u>Preliminary</u>	Results	Biological Reference Interva	al Units
GLOBULIN	2.5	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO	2.0	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	18	0 - 32	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : IFCC WITHOUT PYRIDOXAL-5-PHOSPHATE	8	0 - 33	U/L
ALKALINE PHOSPHATASE METHOD : COLORIMETRIC	66	35 - 104	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : ENZYMATIC, COLORIMETRIC	14	5 - 36	U/L
LACTATE DEHYDROGENASE METHOD : UV ASSAY METHOD	158	135 - 214	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	8	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : JAFFE ALKALINE PICRATE	0.55 Low	0.60 - 1.10	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	14.55	5.0 - 15.0	
URIC ACID, SERUM			
URIC ACID	3.3	2.4 - 5.7	mg/dL
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN METHOD : COLORIMETRIC	7.4	6.4 - 8.3	g/dL
ALBUMIN, SERUM			
ALBUMIN METHOD : BROMOCRESOL GREEN	4.9	3.5 - 5.2	g/dL
GLOBULIN			
GLOBULIN	2.5	2.0 - 4.1	g/dL
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	137.9	136- 145	mmol/L
POTASSIUM, SERUM	4.61	3.50- 5.10	mmol/L
CHLORIDE, SERUM	110.2 High	98 - 107	mmol/L
Interpretation(s)			

Dr.Miral Gajera Consultant Pathologist

Page 13 Of 21







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
	PATIENT ID : KHUSF130290321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		

Test Report Status

Preliminary

Results

Biological Reference Interval Units

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis,	Decreased in: Low potassium	Decreased in: Vomiting, diarrhea,
vomiting, diarrhea, excessive	intake, prolonged vomiting or diarrhea,	renal failure combined with salt
sweating, salt-losing	RTA types I and II,	deprivation, over-treatment with
nephropathy, adrenal insufficiency,	hyperaldosteronism, Cushing's	diuretics, chronic respiratory acidosis,
nephrotic syndrome, water	syndrome,osmotic diuresis (e.g.,	diabetic ketoacidosis, excessive
intoxication, SIADH. Drugs:	hyperglycemia), alkalosis, familial	sweating, SIADH, salt-losing
thiazides, diuretics, ACE inhibitors,	periodic paralysis,trauma	nephropathy, porphyria, expansion of
chlorpropamide, carbamazepine, anti	(transient).Drugs: Adrenergic agents,	extracellular fluid volume,
depressants (SSRI), antipsychotics.	diuretics.	adrenalinsufficiency,
		hyperaldosteronism, metabolic
		alkalosis. Drugs: chronic
		laxative, corticosteroids, diuretics.
Increased in: Dehydration	Increased in: Massive hemolysis,	Increased in: Renal failure, nephrotic
(excessivesweating, severe	severe tissue damage, rhabdomyolysis,	syndrome, RTA, dehydration,
vomiting or diarrhea), diabetes	acidosis, dehydration, renal failure,	overtreatment with
mellitus, diabetesinsipidus,	Addison's disease, RTA type IV,	saline, hyperparathyroidism, diabetes
hyperaldosteronism, inadequate	hyperkalemic familial periodic	insipidus, metabolic acidosis from
water intake. Drugs: steroids,	paralysis. Drugs: potassium salts,	diarrhea (Loss of HCO3-), respiratory
licorice,oral contraceptives.	potassium- sparing diuretics, NSAIDs,	alkalosis, hyperadrenocorticism.
	beta-blockers, ACE inhibitors, high-	Drugs: acetazolamide, androgens,
	dose trimethoprim-sulfamethoxazole.	hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or	Interferences: Hemolysis of sample,	Interferences:Test is helpful in
hyperproteinemi, if sodium analysis	delayed separation of serum,	assessing normal and increased anion
involves a dilution step can cause	prolonged fist clenching during blood	gap metabolic acidosis and in
spurious results. The serum sodium	drawing, and prolonged tourniquet	distinguishing hypercalcemia due to
falls about 1.6 mEq/L for each 100	placement. Very high WBC/PLT counts	hyperparathyroidism (high serum
mg/dL increase in blood glucose.	may cause spurious. Plasma potassium	chloride) from that due to malignancy
	levels are normal.	(Normal serum chloride)

Interpretation(s) GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol

sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycaemics & Insulin treatment, Renal Glycaemic & Insulin response & sensitivity etc.

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of

Dr.Miral Gajera **Consultant Pathologist**



View Report



View Details



PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321	AGE/SEX : 33 Years Female DRAWN :
DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status Preliminary	Results Biological	Reference Interval Units

hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLODD UREA NITROGEN (BUN), SERUM-**Causes** of **Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

 CREATININE, SERUM-Higher than normal level may be due to:
 Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels: Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic

syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy,

Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr.Miral Gajera **Consultant Pathologist**



Page 15 Of 21

View Report

Vie<u>w Details</u>



PERFORMED AT: Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office, Sm Road, Ambawadi, Ahmedabad, 380015 Guirat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in



Units

PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female
	PATIENT ID : KHUSF130290321	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15
8800465156		

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval

CLIN	IICAL PATH - URINALYSIS	 }	
MEDI WHEEL FULL BODY HEALTH CHECKUP I	BELOW 40FEMALE		
PHYSICAL EXAMINATION, URINE			
COLOR	Yellow		
APPEARANCE	Clear		
CHEMICAL EXAMINATION, URINE			
PH METHOD : REFLECTANCE SPECTROPHOTOMETRY	7.0	4.7 - 7.5	
SPECIFIC GRAVITY METHOD : REFLECTANCE SPECTROPHOTOMETRY	1.020	1.003 - 1.035	
PROTEIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE	
GLUCOSE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NEGATIVE	
KETONES METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
BLOOD METHOD : REFLECTANCE SPECTROPHOTOMETRY	DETECTED (+++)	NEGATIVE	
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
UROBILINOGEN METHOD : REFLECTANCE SPECTROPHOTOMETRY	NORMAL	NORMAL	
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE METHOD : REFLECTANCE SPECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS METHOD : MICROSCOPIC EXAMINATION	15 - 20	NOT DETECTED	/HPF
PUS CELL (WBC'S) METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	0-5	/HPF
EPITHELIAL CELLS METHOD : MICROSCOPIC EXAMINATION	10-15	0-5	/HPF
CASTS	NOT DETECTED		

METHOD : MICROSCOPIC EXAMINATION

Dr.Miral Gajera Consultant Pathologist

Page 16 Of 21

View Report







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

CRYSTALS METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	
BACTERIA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED
YEAST METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED
REMARKS	MICROSCOPIC EXAMINAT	ION OF URINE CARRIED OUT ON EDIMENT.

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 17 Of 21

View Report







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 18 Of 21

View Report







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138364 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

	CYTOLOGY	η
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOWR BOUFEMAEDED ING		
PAPANICOLAOU SMEAR	RESULT PENDING	
LETTER	RESULT PENDING	

Page 19 Of 21



View Details View Report





PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000138364	ACCESSION NO : 0321WK000909	AGE/SEX : 33 Years Female	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KHUSF130290321	DRAWN :	
	CLIENT PATIENT ID:	RECEIVED : 25/11/2023 09:38:27	
NEW DELHI 110030	ABHA NO :	REPORTED :27/11/2023 16:15:15	
8800465156			
	I		

Test Report Status	<u>Preliminary</u>
--------------------	--------------------

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE			
MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE			
THYROID PANEL, SERUM			
ТЗ	102.50	Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester:105.0 - 230.0 2nd Trimester:129.0 - 262.0 3rd Trimester:135.0 - 262.0	0
T4	10.51	Non-Pregnant Women 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70)
TSH (ULTRASENSITIVE)	0.914	Non Pregnant Women 0.27 - 4.20 Pregnant Women (As per American Thyroid Associatic 1st Trimester 0.100 - 2.500 2nd Trimester 0.200 - 3.000 3rd Trimester 0.300 - 3.000))

End Of Report Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr.Miral Gajera Consultant Pathologist

Page 20 Of 21







PATIENT NAME : KHUSHBU CHANDARANA	REF. DOCTOR : SELF	
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : 0321WK000909 PATIENT ID : KHUSF130290321 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :33 Years Female DRAWN : RECEIVED :25/11/2023 09:38:27 REPORTED :27/11/2023 16:15:15
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

 It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
 All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.

3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

4. A requested test might not be performed if:

- i. Specimen received is insufficient or inappropriate
- ii. Specimen quality is unsatisfactory
- iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr.Miral Gajera Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. Grand Mall, Opposite Sbi Zonal Office,Sm Road, Ambawadi, Ahmedabad, 380015 Gujrat, India Tel : 079-48912999,079-48913999,079-48914999 Email : customercare.ahmedabad@agilus.in Page 21 Of 21

View Report



